CSPC Pharmaceutical Group Inkomsten in het verleden
Verleden criteriumcontroles 2/6
CSPC Pharmaceutical Group has been growing earnings at an average annual rate of 10.1%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 9.1% per year. CSPC Pharmaceutical Group's return on equity is 16.6%, and it has net margins of 18.7%.
Belangrijke informatie
10.1%
Groei van de winst
10.3%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 5.6% |
Inkomstengroei | 9.1% |
Rendement op eigen vermogen | 16.6% |
Nettomarge | 18.7% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Oct 16Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%
Sep 30CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected
Aug 08Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly
Jun 17CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think
May 29CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14
May 21CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14
Apr 29There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price
Apr 22CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14
Apr 01CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 22Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E
Jan 04Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?
Oct 22Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?
Sep 21CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price
Jul 09Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?
Jun 20CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 01CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11
Apr 04CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price
Mar 12We Think CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt With Ease
Dec 26Opbrengsten en kosten
Hoe CSPC Pharmaceutical Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 31,654 | 5,927 | 10,303 | 5,069 |
31 Mar 24 | 32,380 | 6,057 | 10,872 | 4,992 |
31 Dec 23 | 31,450 | 5,873 | 10,330 | 4,830 |
30 Sep 23 | 31,306 | 6,118 | 10,410 | 4,744 |
30 Jun 23 | 31,407 | 6,092 | 10,973 | 4,406 |
31 Mar 23 | 31,116 | 6,116 | 11,177 | 4,093 |
31 Dec 22 | 30,937 | 6,091 | 11,510 | 3,987 |
30 Sep 22 | 30,721 | 5,738 | 11,915 | 3,845 |
30 Jun 22 | 29,655 | 5,509 | 11,611 | 3,704 |
31 Mar 22 | 29,007 | 5,538 | 11,700 | 3,643 |
31 Dec 21 | 27,867 | 5,605 | 11,453 | 3,433 |
30 Sep 21 | 26,369 | 5,977 | 10,747 | 3,132 |
30 Jun 21 | 26,175 | 5,908 | 10,703 | 3,050 |
31 Mar 21 | 25,551 | 5,472 | 10,332 | 3,013 |
31 Dec 20 | 24,942 | 5,160 | 10,323 | 2,890 |
30 Sep 20 | 24,558 | 4,421 | 10,522 | 2,765 |
30 Jun 20 | 23,515 | 4,150 | 10,287 | 2,511 |
31 Mar 20 | 22,735 | 3,922 | 10,050 | 2,108 |
31 Dec 19 | 22,103 | 3,714 | 9,461 | 2,000 |
30 Sep 19 | 21,335 | 3,625 | 8,887 | 1,928 |
30 Jun 19 | 20,135 | 3,454 | 8,202 | 1,725 |
31 Mar 19 | 18,835 | 3,294 | 7,426 | 1,543 |
31 Dec 18 | 17,717 | 3,081 | 6,841 | 1,342 |
30 Sep 18 | 16,877 | 2,905 | 6,337 | 1,346 |
30 Jun 18 | 15,729 | 2,734 | 5,664 | 973 |
31 Mar 18 | 13,959 | 2,443 | 4,839 | 912 |
31 Dec 17 | 12,877 | 2,307 | 4,178 | 679 |
30 Sep 17 | 12,203 | 2,195 | 3,747 | 277 |
30 Jun 17 | 11,659 | 2,068 | 3,410 | 282 |
31 Mar 17 | 11,383 | 1,979 | 3,203 | 0 |
31 Dec 16 | 11,075 | 1,881 | 2,992 | 0 |
30 Sep 16 | 10,439 | 1,711 | 2,725 | 0 |
30 Jun 16 | 10,118 | 1,607 | 2,576 | 0 |
31 Mar 16 | 9,656 | 1,473 | 2,419 | 0 |
31 Dec 15 | 9,545 | 1,395 | 2,347 | 0 |
30 Sep 15 | 9,284 | 1,305 | 2,202 | 0 |
30 Jun 15 | 9,072 | 1,192 | 2,045 | 0 |
31 Mar 15 | 8,919 | 1,126 | 1,938 | 0 |
31 Dec 14 | 8,762 | 1,015 | 1,871 | 0 |
30 Sep 14 | 8,423 | 896 | 1,748 | 0 |
30 Jun 14 | 8,197 | 849 | 1,686 | 0 |
31 Mar 14 | 8,001 | 814 | 1,627 | 0 |
31 Dec 13 | 7,768 | 760 | 1,500 | 0 |
Kwaliteitswinsten: 1093 has high quality earnings.
Groeiende winstmarge: 1093's current net profit margins (18.7%) are lower than last year (19.4%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 1093's earnings have grown by 10.1% per year over the past 5 years.
Versnelling van de groei: 1093's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 1093 had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.4%).
Rendement op eigen vermogen
Hoge ROE: 1093's Return on Equity (16.6%) is considered low.